{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Dr Agarwals Eye Hospital Ltd
Is Dr Agarwal's Eye overvalued or undervalued?
As of November 27, 2025, Dr Agarwal's Eye is considered overvalued with a valuation grade of expensive, reflected in its high PE ratio of 41.45 and a PEG ratio of 1.95, despite strong long-term returns.
Dr Agarwals Eye Hospital Valuation Shifts Highlight Changing Market Dynamics
Dr Agarwals Eye Hospital has experienced notable shifts in its valuation parameters, reflecting evolving market perceptions within the hospital sector. Recent data reveals adjustments in key metrics such as the price-to-earnings (P/E) ratio and price-to-book value (P/BV), positioning the stock in a different valuation category compared to its historical averages and peer group.
Why is Dr Agarwal's Eye falling/rising?
On 27-Nov, Dr Agarwal's Eye Hospital Ltd witnessed a notable share price increase of 4.73%, closing at ₹5,400.25, reflecting a significant recovery after a period of decline and underpinned by robust quarterly results and positive technical indicators.
Dr Agarwals Eye Hospital Hits Intraday High with Strong 7.44% Surge
Dr Agarwals Eye Hospital demonstrated robust intraday performance on 27 Nov 2025, reaching an intraday high of Rs 5,539.95, reflecting a 7.44% rise from the previous close. The stock outpaced its sector and broader market indices, marking a notable rebound after a sequence of declines.
Dr Agarwals Eye Hospital Sees Shift in Technical Momentum Amid Mixed Market Signals
Dr Agarwals Eye Hospital's stock has experienced a notable shift in technical momentum, reflecting a complex interplay of bullish and bearish signals across various timeframes. While daily moving averages indicate a positive trend, monthly indicators present a more cautious outlook, underscoring the nuanced market assessment of this hospital sector player.
Dr Agarwals Eye Hospital Sees Mixed Technical Signals Amid Price Momentum Shift
Dr Agarwals Eye Hospital's stock has experienced a nuanced shift in price momentum, reflecting a complex interplay of technical indicators across multiple timeframes. Recent evaluation adjustments highlight a transition from a bullish to a mildly bullish trend, with key metrics such as MACD, RSI, and moving averages offering a varied outlook for investors navigating the hospital sector.
Is Dr Agarwal's Eye technically bullish or bearish?
As of November 18, 2025, the technical trend is bullish with moderate strength, supported by bullish MACD and Bollinger Bands, although caution is advised due to mildly bearish monthly indicators.
Dr Agarwals Eye Hospital Technical Momentum Shifts Signal Market Interest
Dr Agarwals Eye Hospital has exhibited a notable shift in its technical parameters, reflecting a change in price momentum and market sentiment. The stock, currently priced at ₹5,250.00, shows a mild bullish trend on weekly charts and a more pronounced bullish stance on daily moving averages, signalling evolving investor interest within the hospital sector.
Is Dr Agarwal's Eye technically bullish or bearish?
As of November 6, 2025, the market trend is mildly bullish, supported by daily moving averages and weekly MACD signals, though caution is advised due to bearish indicators in the monthly data.
Dr. Agarwal's Eye Hospital Shows Mixed Technical Trends Amid Market Volatility
Dr. Agarwal's Eye Hospital has recently revised its evaluation amid market changes, with its stock showing notable volatility over the past year. While it has outperformed the Sensex in the short term, year-to-date performance indicates underachievement, contrasting with its long-term growth potential.
Is Dr Agarwal's Eye overvalued or undervalued?
As of November 4, 2025, Dr Agarwal's Eye is fairly valued with a PE ratio of 40.56, significantly lower than peers like Apollo Hospitals and Max Healthcare, despite a year-to-date decline of -13.74%, while showing a strong long-term gain of 254.76% over three years.
Is Dr Agarwal's Eye overvalued or undervalued?
As of November 4, 2025, Dr Agarwal's Eye is fairly valued with a PE ratio of 40.56, outperforming the Sensex over three years with a 254.76% return, while its peers like Apollo Hospitals and Max Healthcare are significantly more expensive.
Is Dr Agarwal's Eye overvalued or undervalued?
As of November 3, 2025, Dr Agarwal's Eye is considered overvalued with a PE ratio of 41.01 and a year-to-date decline of 12.80%, despite being less expensive than Max Healthcare's PE of 92.86, while Apollo Hospitals presents a more attractive valuation at 71.5.
Is Dr Agarwal's Eye overvalued or undervalued?
As of October 31, 2025, Dr Agarwal's Eye is fairly valued with a PE ratio of 40.18, lower than its peers, despite a year-to-date return of -14.55% compared to the Sensex's 7.42%, but it has outperformed the index with a three-year return of 304.96%, indicating potential for long-term growth.
Dr. Agarwal's Eye Hospital Adjusts Valuation Grade Amid Competitive Market Landscape
Dr. Agarwal's Eye Hospital has adjusted its valuation, showcasing a price-to-earnings ratio of 40.18 and a price-to-book value of 0.80. The company has demonstrated varied stock performance against the Sensex, with a competitive PEG ratio of 1.89 compared to its peers, indicating a favorable market position.
Is Dr Agarwal's Eye overvalued or undervalued?
As of October 31, 2025, Dr Agarwal's Eye is fairly valued at a price of 5,235.70, with a PE ratio of 40.18, an EV to EBITDA ratio of 16.40, and a Price to Book Value of 0.80, making it a reasonable investment compared to its peers, despite a year-to-date decline of -14.55% and strong long-term performance of 304.96% over three years.
Is Dr Agarwal's Eye overvalued or undervalued?
As of October 31, 2025, Dr Agarwal's Eye is fairly valued with a PE Ratio of 40.18, an EV to EBITDA of 16.40, and a Price to Book Value of 0.80, significantly lower than peers like Max Healthcare and Apollo Hospitals, while showing a year-to-date return of -14.55% against the Sensex's 7.42%, but a strong 3-year return of 304.96%.
Is Dr Agarwal's Eye overvalued or undervalued?
As of October 30, 2025, Dr Agarwal's Eye is considered overvalued with a PE ratio of 43.69 and a PEG ratio of 2.94, indicating a premium valuation despite strong historical performance and recent underperformance against the Sensex.
How has been the historical performance of Dr Agarwal's Eye?
Dr Agarwal's Eye has shown significant growth from March 2022 to March 2025, with net sales increasing from 201.21 Cr to 397.15 Cr and profit after tax rising from 24.10 Cr to 54.65 Cr, alongside a substantial rise in total assets and liabilities. The company demonstrates a strong upward trend in profitability and operational cash flow, despite an increase in debt.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
